Cite
High pretreatment disease burden as a risk factor for infectious complications following CD19 chimeric antigen receptor T-cell therapy for large B-cell lymphoma.
MLA
O’Reilly, Maeve A., et al. “High Pretreatment Disease Burden as a Risk Factor for Infectious Complications Following CD19 Chimeric Antigen Receptor T-Cell Therapy for Large B-Cell Lymphoma.” HemaSphere, vol. 8, no. 1, Jan. 2024, p. e29. EBSCOhost, https://doi.org/10.1002/hem3.29.
APA
O’Reilly, M. A., Neill, L., Collin, S. M., Stone, N., Springell, D., Mensah, J., Cheok, K. P. L., Jalowiec, K., Benjamin, R., Kuhnl, A., Roddie, C., & Sanderson, R. (2024). High pretreatment disease burden as a risk factor for infectious complications following CD19 chimeric antigen receptor T-cell therapy for large B-cell lymphoma. HemaSphere, 8(1), e29. https://doi.org/10.1002/hem3.29
Chicago
O’Reilly, Maeve A, Lorna Neill, Simon M Collin, Neil Stone, Deborah Springell, Jeremy Mensah, Kathleen P L Cheok, et al. 2024. “High Pretreatment Disease Burden as a Risk Factor for Infectious Complications Following CD19 Chimeric Antigen Receptor T-Cell Therapy for Large B-Cell Lymphoma.” HemaSphere 8 (1): e29. doi:10.1002/hem3.29.